To date, our study is the largest study to assess for serological markers suggesting in utero infection at a population level in a single hospital where 90% of newborn CBS were tested for SARS-CoV-2 specific anti-RBD and anti-N IgA and IgM antibodies. The gene discussed is CD79A; the disease is infection.